Eric Barbato1, Barbara Daly2, Sara Douglas2, Mary Kerr2, Paul Litman2, Rebecca Darrah1,2. 1. Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA. 2. Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH, USA.
Abstract
INTRODUCTION: Cystic fibrosis (CF) is an autosomal recessive disease that affects many organ systems, most notably the pulmonary and gastrointestinal systems. Through genome-wide association studies, multiple genetic regions modifying CF-related pulmonary and gastrointestinal symptoms have been identified, but translation of these findings to clinical benefit remains elusive. Symptom variation in CF patients has been associated with changes in health-related quality of life (HRQOL), but the relationship between CF symptom-modifying genetic loci and HRQOL has not been explored. The purpose of this study was to determine whether two previously identified genetic modifiers of CF-related pathology also modify the subscales of HRQOL. METHODS: HRQOL and genotype data were obtained and analyzed. Linear regressions were used to examine the amount of variance in HRQOL subscales that could be explained by genotype for each modifier locus. RESULTS: A significant regression equation was found between genotype for rs5952223, a variant near chrXq22-q23, and emotional functioning in a sample of 129 CF patients. DISCUSSION: These data suggest that genotype for this single-nucleotide polymorphism is associated with emotional functioning in CF patients and highlight this genetic region as a potential therapeutic target, irrespective of CF transmembrane conductance regulator genotype.
INTRODUCTION:Cystic fibrosis (CF) is an autosomal recessive disease that affects many organ systems, most notably the pulmonary and gastrointestinal systems. Through genome-wide association studies, multiple genetic regions modifying CF-related pulmonary and gastrointestinal symptoms have been identified, but translation of these findings to clinical benefit remains elusive. Symptom variation in CF patients has been associated with changes in health-related quality of life (HRQOL), but the relationship between CF symptom-modifying genetic loci and HRQOL has not been explored. The purpose of this study was to determine whether two previously identified genetic modifiers of CF-related pathology also modify the subscales of HRQOL. METHODS: HRQOL and genotype data were obtained and analyzed. Linear regressions were used to examine the amount of variance in HRQOL subscales that could be explained by genotype for each modifier locus. RESULTS: A significant regression equation was found between genotype for rs5952223, a variant near chrXq22-q23, and emotional functioning in a sample of 129 CF patients. DISCUSSION: These data suggest that genotype for this single-nucleotide polymorphism is associated with emotional functioning in CF patients and highlight this genetic region as a potential therapeutic target, irrespective of CF transmembrane conductance regulator genotype.
Authors: S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin Journal: Nucleic Acids Res Date: 2001-01-01 Impact factor: 16.971
Authors: J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Rebecca J Darrah; Frank J Jacono; Neha Joshi; Anna L Mitchell; Abdus Sattar; Cara K Campanaro; Paul Litman; Jennifer Frey; David E Nethery; Eric S Barbato; Craig A Hodges; Harriet Corvol; Garry R Cutting; Michael R Knowles; Lisa J Strug; Mitchell L Drumm Journal: J Cyst Fibros Date: 2018-06-22 Impact factor: 5.482
Authors: Scott M Blackman; Clayton W Commander; Christopher Watson; Kristin M Arcara; Lisa J Strug; Jaclyn R Stonebraker; Fred A Wright; Johanna M Rommens; Lei Sun; Rhonda G Pace; Sarah A Norris; Peter R Durie; Mitchell L Drumm; Michael R Knowles; Garry R Cutting Journal: Diabetes Date: 2013-05-13 Impact factor: 9.461